Patient-Focused Treatment Decisions in Pancreatic Cancer: An In-Depth Look at the Role of PARP Inhibitors

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2021 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, grow and divide out of control and form a tumor. In 2020, it is estimated that pancreatic cancer will be responsible for 45,750 deaths and 56,770 new cases. Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths. Despite treatment advances, pancreatic cancer is associated with a relatively poor outcome for most patients. Pancreatic cancer remains among the most challenging malignancies to treat, but ongoing clinical research is continually emerging with the potential to improve outcomes and patient care. Fortunately for patients with pancreatic cancer, several new treatment options, including PARP inhibitors, have become available in recent years or have recently undergone successful late stage clinical trials. They have shown the ability to improve safety and efficacy outcomes, especially in patients with a BRCA mutation. With these recent advances in the management of pancreatic cancer, it is critical to provide medical directors, oncologists, practicing physicians and others on the interprofessional management team with updated clinical trial data and strategies on the changing treatment paradigm, with the ultimate goal of improving patient outcomes.

With the advancement and complexity of different treatment options, clinicians are being challenged to quickly diagnose pancreatic cancer and its corresponding stage, and provide the best evidenced-based treatment that is available for patients. Clinicians are increasingly able to select more potent - and soon, more targeted - options for disease management. In the wake of these advances, other innovative therapies are being rapidly developed, from stroma- and BRCA-targeting agents, to immunotherapy and tumor treating fields. New classes of targeted agents are in development for pancreatic cancer for the first time, including PARP inhibitors. Recent studies have shown that PARP inhibitors have significantly delayed the progression of metastatic pancreatic cancer in patients with BRCA gene mutations. The complexities of today's more personalized care pose multiple challenges to effective clinical and economic management of pancreatic cancer. It is for this reason that medical directors, oncologists, nurses and other healthcare professionals are provided with a detailed overview of current and emerging strategies for pancreatic cancer, with a focus on patient-centric therapy. A review of the most recent clinical trial data for molecularly targeted therapies will be provided, as will a discussion of new and emerging drug classes.

Upon completion of this activity, participants will be able to:

  • Describe the mechanistic rationale for targeting DDR in the treatment of patients with pancreatic cancer

  • Analyze recent clinical data on the safety and efficacy of new and emerging therapies, including PARP inhibitors, for patients with pancreatic cancer

  • Explore the role of PARP inhibitors in the evolving pancreatic cancer treatment paradigm

  • Identify patients with pancreatic cancer that are most likely to benefit from treatments with PARP inhibitors

  • Outline evidence pertaining to biomarker studies that may guide the use of PARP inhibition in pancreatic cancer

  • Assess the managed care considerations of PARP inhibitors by exploring where these agents fit in the current pancreatic management paradigm


Faculty: Tanios Bekaii-Saab, MD, FACP
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
Vice-Chair and Section Lead, Division of Medical Oncology
Senior Associate Consultant, Mayo Clinic AZ


Dr. Bekaii-Saab serves as a consultant for Array Biopharma, Bayer, Boehringer Ingelheim, Celularity, Daiichi Sankyo, Eisai, Exact Science, Genentech, Incyte, Ipsen, Janssen, Merck, Natera, Pfizer, Seattle Genetics, Sobi, and TreosBio. He serves on an advisory board for Imugene, Immuneering, and Sun Biopharma. He has received grants/research support from Agios, Arys, Boston Biomedical, Bayer, Amgen, Merck, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Array Biopharma, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and BMS. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue